Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03660826 · ClinicalTrials.gov registry record · Phase 2
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
A Phase 2 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 288
- Enrollment target
- 20
- Study locations
NCT03660826: Active Phase 2 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma, sponsored by National Cancer Institute (NCI).
NCT03660826 is a Phase 2 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 288 participants, roughly in line with the 318-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target. The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03660826, a Phase 2 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 288 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients with endometrial cancer that has come back (recurrent) or does not respond to treatment (refractory). Olaparib, cediranib, and capivasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Testing the combinations may lower the chance of endometrial cancer growing or spreading compared to usual care.
Primary Outcome
Progression-free survival is defined as the time from the date of study enrollment to the investigator-determined date of progression or death due to any cause, whichever occurs first. For individuals who are alive and progression-free, the censored time at risk will be defined as the time from the study enrollment date to the date of the patient's last radiographic disease assessment.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Bone Marrow Biopsy
- PROCEDURE Bone Marrow Aspirate
- DRUG Capivasertib
- DRUG Cediranib Maleate
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
- Fairbanks Memorial Hospital - Fairbanks
Arizona
- CTCA at Western Regional Medical Center - Goodyear
- Kingman Regional Medical Center - Kingman
- Cancer Center at Saint Joseph's - Phoenix
- Mayo Clinic Hospital in Arizona - Phoenix
- Mayo Clinic in Arizona - Scottsdale
- University of Arizona Cancer Center-Orange Grove Campus - Tucson
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2018-09-27 |
| Est. Completion | 2027-01-21 |
| Phase | Phase 2 |
What the registry record for NCT03660826 still lists
NCT03660826 is an interventional study that assigns participants to a tested intervention. The registered 288 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 318-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target.
The record links to 6 conditions, with Endometrial Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT03660826 names 20 study sites across 4 states, led by Alaska, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03660826 about?
NCT03660826 is a clinical study titled "Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone". This phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients with endometrial cancer that has come back (recurrent) or does not respond to treatment (refractory). Olaparib, cediran...
What is the current status of trial NCT03660826?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 288 participants. The study started on 2018-09-27. Estimated completion is 2027-01-21.
What conditions does trial NCT03660826 study?
This clinical trial studies the following conditions: Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma.
What interventions are being tested in trial NCT03660826?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Bone Marrow Aspirate (PROCEDURE), Capivasertib (DRUG), Cediranib Maleate (DRUG).
Who is sponsoring clinical trial NCT03660826?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03660826 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03660826's enrollment target sits among peer trials
288 4th of 13 higher than 10 of 13 other Endometrial Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
RECRUITING · Phase 2
-
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RECRUITING · Phase 2
-
Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
ACTIVE NOT RECRUITING · Phase 2
-
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
COMPLETED · Phase 2
-
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
- NCT03741777 · 288 participants · NA
Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume
- NCT03937635 · 288 participants · Phase 3
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- NCT04621877 · 288 participants · NA
Lay-Delivered Behavioral Activation in Senior Centers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI